BioNTech Evaluates Rwanda And Senegal For Malaria, Tuberculosis Vaccine Production

by Vandana Singh, Benzinga Editor

August 27, 2021 1:08 PM | 1 min read |

BioNTech SE BNTX is looking into building malaria and tuberculosis vaccine production sites in Rwanda and Senegal.
The Company said that future malaria and tuberculosis vaccines would be based on the so-called messenger RNA technology used in its COVID-19 shot.
BioNTech did not say when production was likely to start. In July, it said it would seek to develop a vaccine for mosquito-borne malaria, eyeing production in Africa.
Related Content: After COVID-19, BioNTech Plans To Develop an mRNA Vaccine To Prevent Malaria
The sites would be near prospective vaccine hubs planned by the World Health Organization (WHO), the Company added.
Price Action: BNTX shares are down 2.57% at $360.47 during the market session on the last check Friday.

Posted In:

Biotech Government News Health Care General Briefs malaria

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.